Study on Colonic Fermentation in Chronic Kidney Disease Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- difference in fecal metabolite profile (Chronic kidney disease vs. control)
研究概览
简要总结
Chronic kidney disease is associated with the accumulation of various metabolites, i.e., uremic retention solutes. Evidence is mounting that the colonic microbiome contributes substantially to these uremic retention solutes. Indoxyl sulfate and p-cresyl sulfate are among the most extensively studied gut microbial metabolites, and are associated with cardiovascular disease, chronic kidney disease progression and overall mortality. Indirect findings suggest that chronic kidney disease influences the colonic microbial metabolism with higher p-cresyl sulfate urinary excretion rates at more advanced renal disease. Therefore, this study aims to elucidate the influence of renal dysfunction on microbial metabolism and to test the hypothesis that chronic kidney disease patients carry a different fecal metabolite profile.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥ 18 and ≤ 95 years
- •Treatment with renal replacement therapy, i.e. hemo- or peritoneal dialysis for more than 3 months
- •Written informed consent
排除标准
- •History of organic gastro-intestinal disease (e.g., inflammatory bowel disease, malignancy)
- •History of colonic surgery
- •Recipient of a renal or other solid organ transplant
- •Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks
结局指标
主要结局
difference in fecal metabolite profile (Chronic kidney disease vs. control)
时间窗: baseline
difference in fecal metabolite profile between chronic kidney disease patients and control group
次要结局
- difference in fecal metabolite profile depending on dialysis modality(baseline)